Aastrom Biosciences Announces Strategic Change in Research and Development Programs to Focus on Dilated Cardiomyopathy and Other Rare Disease Indications

[at noodls] – Focus shifted to Phase 2b ixCELL-DCM clinical study and the development of ixmyelocel-T for dilated cardiomyopathy, an orphan drug indication. Company to stop enrollment and end Phase 3 REVIVE CLI study … more

View todays social media effects on ASTM

View the latest stocks trending across Twitter. Click to view dashboard

See who Aastrom is hiring next, click here to view